Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AC Immune SA ( (ACIU) ) has issued an update.
On April 7, 2026, AC Immune SA announced it had amended its 2018 license and collaboration agreement with Eli Lilly to advance Tau aggregation inhibitor small molecules, including new lead Morphomer Tau candidates and backup compounds, for potential treatment of Alzheimer’s disease and other neurodegenerative disorders. The revised deal brings AC Immune a CHF 10 million upfront payment, a milestone tied to Phase 1 dosing, and eligibility for more than CHF 1.7 billion in further development, regulatory and commercial milestones plus low double-digit tiered royalties, strengthening its funding base and reinforcing its strategic position as a key player in Tau-targeted neurodegeneration drug development.
The most recent analyst rating on (ACIU) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on AC Immune SA stock, see the ACIU Stock Forecast page.
Spark’s Take on ACIU Stock
According to Spark, TipRanks’ AI Analyst, ACIU is a Neutral.
The score is primarily held back by weak financial performance driven by ongoing losses, a 2025 revenue decline, and a return to significant cash burn, despite low debt. Technical indicators are mixed and only modestly supportive, while valuation metrics offer limited support because earnings are negative and no dividend yield is available.
To see Spark’s full report on ACIU stock, click here.
More about AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company focused on precision prevention and treatment of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and certain rare disorders driven by misfolded proteins. The Swiss group leverages its SupraAntigen and Morphomer technology platforms to develop first- and best-in-class therapeutic and diagnostic candidates, supported by multiple big-pharma partnerships and large potential milestone streams.
Average Trading Volume: 293,477
Technical Sentiment Signal: Sell
Current Market Cap: $274.8M
See more insights into ACIU stock on TipRanks’ Stock Analysis page.